

OPTIMA HEALTH PLAN

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: *The prescribing physician must sign and clearly print the name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. Incomplete form will delay authorization process.*

Drug Requested: Stivarga® (regorafenib)

DRUG INFORMATION: Please complete information below. Incomplete information will delay authorization process.

Drug Form/Strength/Quantity: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Dosage/Administration Recommendation: The recommended dose is 160 mg (four 40 mg tablets) taken orally once daily, with a low-fat breakfast, for the first 21 days of each 28 day cycle

CLINICAL CRITERIA: ALL applicable boxes must be checked to qualify. If not checked, authorization process will be delayed.

- Patient has metastatic colorectal cancer (mCRC)
 - Patient has been previously treated with:
 - FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan)
- AND**
- Anti-VEGF therapy (e.g., bevacizumab) OR Anti-EGFR therapy (e.g., panitumumab or cetuximab) if KRAS wild type mCRC

OR

- Patient has advanced gastrointestinal stromal tumor (GIST)
 - Tumor cannot be surgically removed OR Cancer is metastatic
 - Tumor is no longer responsive to imatinib (Gleevec) and sunitinib (Sutent)

OR

- Patient has hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Medication being provided by a Specialty Pharmacy: Briova SpecialtyRx

****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.****

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.

Patient Name: _____

Member Optima #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

DEA OR NPI #: _____

*Approved by Pharmacy and Therapeutics Committee: 2/21/2013

REVISED/UPDATED: 3/21/2013; 5/20/2013; 9/24/2014; 11/5/2014; 5/22/2015; 12/29/2015; 9/22/2016; 11/29/2016; 12/13/2016; 9/18/2017; 10/7/2017.